SILVER-LAKE/SILAE
Silae, a specialist provider of cloud-based payroll and HR software for the French market, and Silver Lake, a global technology investment firm, today announced that Silver Lake is to acquire 100% of Silae from its founding shareholders, who intend to remain involved in the business.
Jean-Paul Bagou, Michel Delolme, Didier Fléchet, Philippe Marty and Daniel Mayet, co-founders of Silae, said: “As a founder group, we are extremely proud of what Silae has achieved over the past decade. Together with our exceptional and talented employees and partners, we have built a highly successful company and laid a strong foundation for the future by developing a suite of leading SaaS Payroll and HR software products and continuously improving our customer service. As Silae begins an exciting new chapter of product innovation and growth, we are thrilled to partner with Silver Lake, a world-class technology investor with deep software industry expertise and value creation capabilities. This investment marks an acceleration point for our company, employees, customers and partners, as we gain further strength to reinforce our current position in the market while continuing to develop new innovative products and services.”
Christian Lucas, Co-Head of Silver Lake EMEA said: “We want to thank all five founders of Silae for entrusting us with the very special company that they have built over the past decade. We are highly impressed by how, together with employees, they have built Silae into an outstanding and fast-growing company, with an established track record of providing best-in-class SaaS solutions in the payroll and HR segments. Investing in high-growth, innovative, founder-led technology businesses is at the core of Silver Lake’s DNA and it is a privilege to partner with the current team. As the company enters a new phase of value creation, we look forward to continuing working with them and we intend to invest in the company’s continued success to further strengthen its technology platform, as well as its products and services offered to its current and future clients.”
Founded in 2010 and headquartered in Aix-en-Provence, France, Silae is a specialist provider of fully cloud-based Payroll and HR software, offering a range of SaaS solutions and cloud services to simplify and automate complex processes for more than 550,000 businesses in France in close partnership with a wide network of CPAs and HR outsourcing specialists. Silae’s proprietary and highly automated core software platform Silaexpert provides unique scalability to its partner network, enabling substantial efficiency increases along the HR process chain and attracting a rapidly growing number of customers and partners. Silae has established a strong trajectory of growth and profitability increases, more than doubling its revenue and tripling its EBITDA over the past two years. In 2020, Silae is on track to reach a further major milestone on its growth path by becoming the trusted partner for more than 4 million employees in France who will have their payroll slips processed by the company’s solutions.
Silver Lake is planning to invest in Silae and support it in its next phase of development as the company is set to further accelerate its growth, through innovative new products such as its employee engagement solution PaiePilote, as well as to build on its strong technology expertise to extend its product offering while keeping its identity and continuing to provide best-in-class service to its customers. Silver Lake will thereby preserve Silae’s existing operating model, strengthen it further and make its offering even more accessible to customers.
Financial terms of the transaction were not disclosed. The transaction is expected to close in the third quarter subject to regulatory approval.
About Silae
Founded in 2010 and headquartered in Aix-en-Provence, France, Silae is a provider of cloud-based Payroll and HR software, offering a broad range of solutions to more than 550,000 businesses in partnership with its strong network of CPA and HR outsourcing partners. The company’s core SaaS product line Silaexpert enables full automation of complex payroll and HR processes, ensuring full adherence with constantly evolving labour and tax regulations in France and facilitating seamless communication and data exchange between outsourcing partners and customers in a highly collaborative environment. For more information, please visit silaexpert.fr.
About Silver Lake
Silver Lake is a global technology investment firm, with over $40 billion in combined assets under management and committed capital and a team of approximately 100 investment and operating professionals located in Silicon Valley, New York, London and Hong Kong. Silver Lake’s portfolio of investments collectively generates more than $230 billion of revenue annually and employs 370,000 people globally. For more information about Silver Lake and its portfolio, please visit silverlake.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005948/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom